Brain-derived neurotrophic factor (BDNF) is a neurotrophin hypothesized to play an important role in mammalian sleep expression and regulation. In order to investigate the role of the truncated receptor for BDNF, TrkB.T1, in mammalian sleep, we examined sleep architecture and sleep regulation in adult mice constitutively lacking this receptor. We find that TrkB.T1 knockout mice have increased REM sleep time, reduced REM sleep latency, and reduced sleep continuity. These results demonstrate a novel role for the TrkB.T1 receptor in sleep expression and provide new insights into the relationship between BDNF, psychiatric illness, and sleep.
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TrkB; TrkB.T1; brain-derived neurotrophic factor; neurotrophins; REM sleep NEUROTROPHINS ARE NEUROPEPTIDES that promote brain cell survival and synaptic plasticity (44) . They have also been implicated in mammalian sleep (1, 12, 31, 33, 37, 43) . Among the neurotrophins, substantial evidence supports a role for brainderived neurotrophic factor (BDNF). BDNF can influence sleep by affecting sleep expression or sleep homeostasis, a regulatory process that controls the accumulation and discharge of sleep drive (2) . For example, sleep deprivation (SD) increases the expression of BDNF mRNA in the rodent brain (6, 21, 37, 51) . Intracerebroventricular injection of BDNF leads to increases in non-rapid eye movement (NREM) sleep in rats and increases both NREM and rapid eye movement (REM) sleep in rabbits (31) . The effects of BDNF on indices of sleep need [e.g., NREM slow-wave activity (SWA) (2, 17) ] are less clear. BDNF reduces NREM SWA when administered intracerebroventricularly (31) but triggers a localized increase in SWA when injected intracortically (12) . Moreover, in humans a single nucleotide polymorphism that reduces BDNF release is associated with less stage 4 NREM sleep and lower NREM SWA (1) .
The precise signaling pathways governing the effects of BDNF on sleep are unknown. BDNF exerts its effects through two predominant isoforms of the TrkB receptor (13, 24) . One isoform contains a tyrosine kinase (TrkB.FL) and a second, truncated isoform lacks the kinase domain (TrkB.T1). TrkB.FL is predominantly expressed in neurons, whereas TrkB.T1 shows substantially higher expression in glia (13) . This differential expression may be important for the effects of TrkB.T1. When expressed in neurons, TrkB.T1 is thought to decrease TrkB.FL function (10, 11) . However, in astrocytes TrkB.T1 triggers intracellular signaling cascades [e.g., via Rho guanosine triphosphatases (GTPases) and inositol triphosphate-mediated calcium release (39, 46) ], which may alter astrocyte function and morphology (8, 38) . Astrocytes, in turn, play a role in sleep homeostasis and mediate cognitive impairments incurred by sleep loss (22) . Both TrkB.FL and TrkB.T1 receptors are expressed in brain regions important for mammalian sleep regulation (50, 56) , but their relative contribution to sleep is poorly understood.
To explore the role of the TrkB.T1 receptor in sleep, we examined sleep expression and homeostasis in mice constitutively lacking the TrkB.T1 receptor. TrkB.T1-null mice exhibit heightened anxiety and structural changes in the amygdala (5), yet sleep has not been previously examined in these mice. We find that TrkB.T1 knockout mice have normal NREM sleep time and NREM sleep homeostasis, but show multiple sleep alterations reported in mood disorders. These include increased REM sleep time, reduced REM sleep latency, and sleep fragmentation (i.e., shorter bouts of total sleep and wake), similar to the reduced sleep continuity reported in major depressive disorders (40) . These results support a novel role of the TrkB.T1 in mammalian sleep and suggest that this BDNF receptor may provide a link between sleep abnormalities and psychiatric illness.
MATERIALS AND METHODS
Animals and surgery. Transgenic C57/BL6 mice lacking the TrkB.T1 receptor (n ϭ 10) and their wild-type siblings (n ϭ 9) were obtained from Dr. Susan Dorsey (University of Maryland, Baltimore, MD). The generation of these mice has been previously described (10) . Mice were housed in a satellite facility under standard environmental conditions (temperature: 22 Ϯ 2°C, humidity: 30 Ϯ 10%), maintained on a 12:12-h light-dark cycle with lights on at 0730 [zeitgeber time (ZT) 0], and provided food and water ad libitum. Male mice 5-7 mo in age underwent surgical implantation for polysomnographic sleep recordings. Briefly, animals were administered antibiotics and buprenorphine for pain management and then were anesthetized with isoflurane. Four stainless-steel wire EEG electrodes were implanted epidurally (A/P: ϩ1.5 mm and Ϫ3.0 mm, M/L: Ϯ1.7 mm, from bregma) and two EMG electrodes were inserted into the nuchal muscle, as previously described (14, 52) . Animals were returned to their home cages, administered additional antibiotics and analgesics, and allowed to recover for 5 days prior to acclimation. All experiments were performed with the approval of the University of Pennsylvania Institutional Animal Care and Use Committee and conformed to the National Institutes of Health Office of Laboratory Animal Welfare Policy.
Polysomnographic recordings. Each animal was singly housed under a strict 12:12-h light-dark cycle, connected to a lightweight, flexible cable and acclimated to recording conditions for 6 days. EEG and EMG signals were amplified and filtered (lowpass cutoffs at 100 Hz, highpass cutoffs at 0.3 and 10 Hz, respectively) on a model 15LT system (Astro-Med, West Warwick, RI), sampled at 256 Hz using Contec A/D cards and recorded with Vital Recorder (Kissei Comtec America, Irvine, CA).
We investigated sleep during baseline conditions and again in response to SD in order to determine the homeostatic response to sleep loss. Following 24 h of baseline recording, mice were sleepdeprived (SD) for 6 h beginning at lights on using gentle handling. Procedures used to keep the mice awake consisted of light brushing, tapping on cages, and the introduction of novel objects (17) . We analyzed the 18-h recovery period immediately following SD for changes in sleep architecture and EEG activity.
Vigilance state scoring and analysis. We scored EEG and EMG recordings using SleepSign (Kissei Comtec) in 4-s epochs as wake, NREM sleep, or REM sleep according to previously reported methods (22) . We first investigated the mean EEG power spectra of each state to ensure that no differences between knockout and wild-type mice affected the proper scoring of states. We performed a fast Fourier transform on EEG epochs convolved with a Hanning window to determine the signal power in frequencies from 0.5 to 20 Hz. The power spectra for each vigilance state was expressed as a percentage of the total power across all frequencies and states during the baseline recording (14) . Epochs containing artifacts were excluded from spectral analysis. NREM SWA (0.5-4.0 Hz) was averaged in 2-h bins for baseline and recovery periods. SWA for individual animals was expressed as a percentage of values in the final 4 h of the baseline light phase, as described previously (16) .
We next investigated sleep and wake architecture. Vigilance state time was expressed as a percentage of total recording time. "Total sleep" was calculated as combined NREM and REM sleep time. We calculated vigilance state bout frequency and duration according to previously published methods (52) . Bouts of wake and NREM sleep were identified as consecutive epochs longer than 30 s in duration, while REM sleep bouts were identified as consecutive epochs greater than 20 s. Total sleep bouts were identified as 30 s or more of either NREM or REM sleep. A bout was considered terminated when it was interrupted by 30 s of any other state (e.g., the presence of 30 s of wakefulness in an ongoing NREM or total sleep bout) (52) . We calculated these measures over 24 h, as well as separately for the light phase and dark phase. REM sleep latency was also calculated as previously described (52) . Briefly, REM sleep latency was defined as the duration of NREM sleep preceding a bout of REM sleep, interrupted by periods of wakefulness shorter than 30 s. Initial inspection of the bout duration and REM latency data indicated that these data were not normally distributed. Therefore, we analyzed these data with empirical cumulative distribution functions using the ecdf function of the MatLab Statistics Toolbox (MathWorks, Natick, MA). All bouts for each vigilance state [in the 24-h baseline or 18-h recovery period after total sleep deprivation] were pooled across animals for each genotype.
NREM sleep homeostasis. We calculated several metrics to identify potential differences in sleep homeostasis between genotypes. NREM SWA following SD was averaged in 2-h bins and normalized to the last 4 h of the baseline period (16) . We then determined changes in total, NREM, and REM sleep time for the entire recording period and in 2-h bins (17) . Compensatory changes in bout duration were also examined in a comparable manner for the entire 18-h recovery period (19) . REM sleep homeostasis. In order to investigate REM sleep homeostasis directly, a subset of mice (n ϭ 4 each genotype) underwent 6 h of selective REM sleep deprivation (RSD) 2 mo after the total sleep deprivation experiment. RSD began 2 h into the light phase when REM sleep pressure is highest (26) . Vigilance state was monitored visually in real time using EEG and EMG, and mice were gently awakened upon entering REM sleep (26) . The 4 h immediately following RSD were analyzed for compensatory changes in REM sleep time.
Immunofluorescence. We collected brain tissue from the mice used in sleep experiments to examine regional TrkB.T1 receptor expression. Mice were anesthetized with isoflurane and euthanized with pentobarbital sodium (200 mg/kg) and then perfused transcardially with 20 ml of ice-cold PBS followed by 20 ml of ice-cold 4% paraformaldehyde (PFA; Electron Microscopy Sciences, Hatfield, PA). Brains were removed, postfixed overnight in 4% PFA in PBS at 4°C, washed and cryoprotected in 30% sucrose in PBS at 4°C. Tissue was frozen, cut into 30-m coronal sections with a cryostat (Leica Microsystems, Buffalo Grove, IL), and processed as free-floating sections for immunofluorescence. Slices were washed with 0.25% Triton X-100 (Roche Diagnostics, Indianapolis, IN) in PBS-Tween (PBS-T), blocked with 5% normal donkey serum (Sigma-Aldrich, St. Louis, MO), and incubated with primary antibodies in PBS-T with 5% serum at 4°C overnight. We used a rabbit polyclonal antibody to TrkB.T1 (Santa Cruz Biotechnology, Dallas, TX; 1:50) and a goat polyclonal antibody to choline acetyltransferase (Millipore, Billerica, MA; 1:250) as primary antibodies. Slices were incubated with donkey Alexa fluorophore-conjugated secondary antibodies (Life Technologies, Grand Island, NY; 1:250) and coverslipped with Vectashield mounting media (Vector Laboratories, Burlingame, CA). Images were acquired sequentially with an SP5 laser-scanning confocal microscope (Leica Microsystems) using identical settings for images from both genotypes.
Statistical analyses. We compared measures from wild-type and TrkB.T1 knockout mice with two-factor, repeated-measures ANOVAs with factors "genotype" and "time" when more than two comparisons were made. To evaluate the effects of selective REM sleep deprivation, we used repeated-measures ANOVAs with factors "recording day" and "time" within each genotype. We used the Holm-Sidak post hoc test when significant main effects or interactions were found using ANOVA. Wilcoxon-Mann-Whitney tests were used for single comparisons between genotypes since data were frequently nonparametric. We used Kolmogorov-Smirnov (K-S) tests to compare the distributions of bout lengths between genotypes. Statistics were calculated using SigmaPlot 11.0 (Systat Software, San Jose, CA) and the MatLab Statistics Toolbox (MatLab version R2013a; MathWorks).
RESULTS
Baseline spectral analysis, vigilance state time and sleep architecture. Spectral analysis of sleep and wake EEG revealed no significant differences between the knockout and wild-type mice (Fig. 1, A-C) , nor any significant differences in the variation of NREM SWA across the 24-h day (Fig. 1D ). There were also no differences in Wake or NREM sleep time as a percentage of total recording time (Fig. 2, A-C) . However, we did find that knockout mice spent significantly more time in REM sleep ( Fig. 2A) . This difference in REM sleep was most apparent in the light phase (Table 1 ; Fig. 2D ).
Vigilance state bout durations and REM latencies were also different between the two groups of mice. Mean values for the vigilance states were similar between the two groups of mice (Table 1) , but cumulative histogram analyses revealed that total sleep, Wake, and NREM sleep bouts were significantly skewed toward shorter duration in the knockout mice (Fig. 3,  A-C) . In contrast, the distribution of REM bouts was skewed toward longer duration (Fig. 3D) . REM sleep latencies were also significantly skewed to shorter duration in the TrkB.T1 knockout mice (Fig. 3E) .
Sleep homeostasis in the TrkB.T1 knockout mice. We examined several indices of sleep homeostasis to determine whether sleep regulation was altered in TrkB.T1 knockout mice. There was no difference in the effectiveness of SD between knockout Values are expressed as means Ϯ SE. Sleep parameters were determined by polysomnography during a baseline recording and during recovery from sleep deprivation. L, light cycle; D, dark cycle; WT, wild-type (n ϭ 9); KO, TrkB.T1 knockout (n ϭ 10). *P Ͻ 0.05 between WT and KO values, Mann-Whitney U-test. and wild-type mice (wake time during SD: 98.0 Ϯ 0.6% and 99.0 Ϯ 0.4%, respectively; means Ϯ SE). As shown in Fig. 4A , wild-type and knockout mice responded with a similar increase in SWA during the recovery period. We also examined compensatory increases in sleep time following SD. When hours ZT 6 to ZT 24 were compared, the two groups of mice also showed similar compensatory increases in total sleep time between the baseline and recovery periods (knockout: 34.5 Ϯ 1.0% and 46.3 Ϯ 2.3%; wild-type mice: 32.9 Ϯ 1.4% and 42.9 Ϯ 1.6%; P Ͻ 0.001, Mann-Whitney U-tests). There were also no significant differences in compensatory changes in wake or NREM sleep time between the groups of mice (Fig. 4B) . REM sleep remained elevated in knockout mice during the recovery period compared with wild-type (Fig. 4B) . This was mainly restricted to the latter half of the dark phase (Table 1) . A cumulative histogram analyses of bout durations showed that NREM sleep bouts in knockout (but not wild-type) mice were significantly skewed to longer durations during the recovery period (relative to baseline, Fig. 4D ). In addition, average REM sleep bout durations were significantly higher during the dark period in knockout mice relative to wild-type values (Table 1) . REM sleep latencies were also skewed toward longer latencies in the knockout mice relative to baseline (Fig. 4H ), but this did not occur in wild-type mice (Fig. 4G) . We performed a supplementary selective RSD experiment to more directly probe REM sleep homeostasis in the TrkB.T1 knockout mice. There was no difference in the effectiveness of the 6-h RSD between knockout and wild-type mice (REM sleep time during RSD: 2.2 Ϯ 0.4% and 2.7 Ϯ 0.5%, respectively; mean Ϯ SE). Wild-type mice showed a significant increase above baseline values in REM sleep during recovery from RSD, whereas the knockout mice displayed a blunted rebound (Fig. 4I) .
TrkB.T1 immunolabeling. We examined brain slices from wild-type and knockout mice labeled for TrkB.T1 to determine regions where the loss of TrkB.T1 may affect REM sleep. Widespread TrkB.T1 labeling was observed in wildtype mice, and selected brain areas known to play a role in REM sleep regulation were examined further (36, 49) . In wild-type mice, TrkB.T1 labeling was observed in several brain stem nuclei, including the cholinergic neurons of the laterodorsal tegmental area (LDT; Fig. 5B ) and pedunculotegmental nucleus (data not shown). Additionally, the caudal pontine and oral pontine reticular nuclei, subcoeruleus nucleus and ventrolateral periaqueductal gray all displayed substantial TrkB.T1 labeling (data not shown). In the forebrain, wild-type mice also displayed TrkB.T1 expression in the lateral hypothalamus (Fig. 5E ), preoptic hypothalamus, and amygdala (data not shown), although at lower intensity than in the brain stem. As expected, TrkB.T1 labeling in the brain stem and forebrain of knockout mice was at background levels (Fig. 5, C and F) .
DISCUSSION
In this study, we determined whether the neurotrophin receptor TrkB.T1 plays a role in sleep. We found that TrkB.T1 deletion increases REM sleep time, REM bout duration, and sleep fragmentation, and decreases REM sleep latency. Deletion of TrkB.T1 also resulted in subtle abnormalities in sleep homeostasis. NREM SWA (a classic index of sleep homeostasis) was similar in wild-type and knockout mice in the baseline period and after sleep deprivation. However, knockout mice showed changes in NREM bout duration and REM sleep latencies during recovery that were not observed in wild-type mice. Selective REM sleep deprivation also produced an attenuated "REM rebound" in knockout mice. While we cannot exclude the possibility that embryonic deletion of the TrkB.T1 receptor influenced the adult phenotype, this seems unlikely for the following reasons. Overt developmental abnormalities are not observed in TrkB.T1 knockout mice (5), and indirect compensatory effects are limited by the late postnatal onset of TrkB.T1 expression (50) . We discuss the implications of our main findings below.
These results provide new insights into the role of BDNF in sleep expression and regulation. Whole brain and cortical BDNF protein and mRNA increase with wakefulness (6, 21, 51) . BDNF increases NREM sleep time when administered intracerebroventricularly (31) and may influence NREM SWA (1, 12, 25, 31) . The fact that TrkB.T1 deletion had no impact on NREM sleep time or NREM SWA indicates that TrkB.T1 does not play a major role in these aspects of sleep. On the other hand, NREM sleep bouts after SD were skewed toward longer duration in knockout mice (but not wildtype), suggesting that other differences in compensation may exist. An additional, unusual finding is the fragmentation of sleep combined with increased REM sleep time, longer REM bout duration, and decreased REM sleep latency in the TrkB.T1 knockout mice. Other mutant mice exhibit altered REM sleep time or bout duration (3, 9, 27, 28) , and sleep fragmentation itself is a relatively common finding among studies of knockout mice (reviewed in Ref. 29 ). Consequently, it is possible that the changes in REM sleep and sleep fragmentation are unrelated, or mediated, by multiple effects of a constitutive knockout. To our knowledge, however, this entire suite of changes has not been previously found following deletion of a single membranebound receptor.
Our results provide new clues about the relationship between sleep, BDNF and psychiatric illness. Manipulating the expression or activity of TrkB isoforms has been used to explore mouse models of major depressive disorder (MDD) (reviewed in Ref. 33 ), but the relationship between these models and sleep has not been explored. We demonstrate that TrkB.T1 knockout mice display increased REM sleep and REM bout duration, decreased latency to REM sleep, and abnormal REM sleep regulation. These sleep abnormalities are reported in depressed patients and animal models of depression (42, 53) , suggesting that reduced signaling through TrkB.T1 may mediate some changes in sleep architecture associated with psychiatric illness. Moreover, the 15-20% increase in REM sleep above wild-type values that TrkB.T1 knockout mice exhibit is similar to the increase observed in rodent models of MDD (53) and human studies of MDD (18, 45) . It is unknown whether this amount of REM sleep directly influences MDD or is merely a risk factor for its progression. However, it is interesting to note that the majority of antidepressant drugs suppress REM sleep, and normalization of REM sleep parameters is a strong correlate of remission (40) . Our results were obtained in male mice, and it will be important to examine sleep in female TrkB.T1 knockout mice in the future given the higher prevalence of MDD in women.
Our findings also provide insights into the relationship between stress and changes in REM sleep. Stress-mediated activation of the amygdala is known to influence REM sleep, as mice exposed to a controllable stressor exhibit increased REM sleep time (48) . This increase is thought to result from heightened activity in the central nucleus of the amygdala and its projections to brain stem nuclei important for sleep (47) . Interestingly, TrkB.T1 knockout mice spend less time in the open arm of the elevated plus maze (5), an indication of increased anxiety, and are known to have altered neuronal morphology in the basolateral amygdala (5). Thus, our results link BDNF receptor-dependent changes in anxiety to sleep abnormalities seen in mood disorders.
Perspectives and Significance
Our results raise several interesting questions. First, where in the brain do TrkB.T1 receptors exert their effects on sleep? Brain stem nuclei are central to REM sleep generation and regulation (reviewed in Refs. 36 and 49). In the brain stem, the neurotrophins NGF and NT-3 are known to elicit REM sleep when injected into the pontine brain stem of the cat (54, 55) . It is unknown whether BDNF also induces REM sleep when injected in a similar fashion, but extensive labeling for TrkB was reported in the same region as receptors for NGF and NT-3 (56) . Other brain regions that influence REM sleep in rodents include the lateral hypothalamus (7), extended ventrolateral preoptic nucleus (35) , median preoptic nucleus (20) , and central nucleus of the amygdala (48) . We find that the TrkB.T1 receptor is highly expressed in comparable brain stem and forebrain regions in mice (Fig. 3) , which is suggestive of brain regions where the loss of TrkB.T1 may influence REM sleep.
A second question is what are the cellular events triggered by TrkB.T1 that alter sleep? The deletion of TrkB.T1 likely has two effects. The first is a loss of dominant-negative inhibition of the TrkB.FL receptor in neurons, the second is the absence of TrkB.T1-mediated signaling cascades in astrocytes. Regarding the first possibility, there is evidence that the effects of BDNF on sleep depend on tyrosine kinase activation. Specifically, the increase in NREM SWA after cortical BDNF injection is prevented by coadministration of the tyrosine kinase inhibitor K252a (12) . The second possibility is that disruption of TrkB.T1 signaling in astrocytes contributes to our results. TrkB.T1 signaling mechanisms in astrocytes include the activation of Rho GTPases (39), inositol triphosphate-mediated intracellular calcium release (46) , and the production of nitric oxide (8) . The intracellular release of calcium from astrocytes is thought to trigger the release of glial signaling molecules (23), including, possibly, several cytokines and growth factors known to influence sleep (15, 30, 32) . This suggests that the deletion of TrkB.T1 may reduce the release of glial signaling molecules, which has been implicated in MDD (4) .
